Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Postsynaptic alpha-neurotoxins are a critical class of three-finger toxins (3FTxs) found in the venom of elapid snakes, including cobras, kraits, and sea snakes. These small proteins are characterized by a distinct structural motif consisting of three beta-stranded loops extending from a central core, stabilized by multiple disulfide bonds (Kini, 2002). Their primary biological role is to induce rapid paralysis in prey by binding with extreme specificity and high affinity to the nicotinic acetylcholine receptors (nAChRs) located at the postsynaptic membrane of the neuromuscular junction (Tsetlin, 1999). By competitively inhibiting acetylcholine binding, they prevent the depolarization of the muscle fiber, leading to flaccid paralysis and, in humans, potentially fatal respiratory arrest (Barber et al., 2013). In the pharmaceutical and biotech sectors, these toxins are the primary targets for the development of antivenoms and synthetic neutralizing agents. Furthermore, their high selectivity has made them invaluable molecular probes for mapping the structure of cholinergic receptors and studying neuromuscular transmission (Nirthanan & Gwee, 2004).
Drugs targeting these toxins, primarily antivenoms, work through direct neutralization by binding to the toxin and preventing its interaction with the nicotinic acetylcholine receptor. Additionally, acetylcholinesterase inhibitors like neostigmine are used to increase the concentration of acetylcholine at the neuromuscular junction, thereby competitively displacing the toxin from the receptor and restoring muscle function (Tsetlin, 1999).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Postsynaptic alpha-neurotoxin (α-neurotoxin) (α-neurotoxin).